Adial Pharmaceuticals has acquired Azora Therapeutics, gaining its lead drug candidate AT177, a colon-targeted treatment for ulcerative colitis designed to minimize systemic exposure and safety risks. Concurrently, Adial secured up to $64 million in private financing, including an initial $32 million upfront, to fund clinical development milestones, including Phase 1 trials planned for mid-2027. This acquisition and financing position Adial to advance a potentially best-in-class therapy addressing a significant unmet medical need in ulcerative colitis. The company also appointed Dr. Wendy Young to its board to support growth and drug development expertise.
Ultragenyx Pharmaceutical Inc. awarded 44,409 restricted stock units to 15 newly hired non-executive officers under its Employment Inducement Plan. The grants, approved by the compensation committee, vest over four years with 25% vesting annually, co...
Nyxoah has announced an extraordinary general meeting of shareholders set for July 9, 2026, at its headquarters in Belgium. The meeting will discuss renewing the authorization for the board to increase the company's capital over the next five years, ...
Eupraxia Pharmaceuticals held its Annual General Meeting on June 18, 2026, where shareholders elected all seven board nominees proposed by management with strong majority votes. Additionally, KPMG LLP was reappointed as the company's auditor for the ...
Cate & Chloe is discounting its Bianca 18k Gold-Plated Crystal Hoop Earrings to $19.98 from $86 during Amazon Prime Day 2026, running June 23-26. This 77% markdown aligns with growing consumer demand for affordable luxury jewelry, with earrings price...
At its 2026 annual general meeting, Dynacor Group appointed COO Daniel Misiano as the new President & CEO, succeeding Jean Martineau who remains on the board. All nominated directors were re-elected, and the company approved Raymond Chabot Grant Thor...
